T-lymphocyte-derived enkephalins reduce T.sub.h1/T.sub.h17 colitis and associated pain in mice

Background Endogenous opioids, including enkephalins, are fundamental regulators of pain. In inflammatory conditions, the local release of opioids by leukocytes at the inflammatory site inhibits nociceptor firing, thereby inducing analgesia. Accordingly, in chronic intestinal T.sub.h1/T.sub.h17-asso...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of gastroenterology 2018-02, Vol.53 (2), p.215
Hauptverfasser: Basso, Lilian, Garnier, Laure, Bessac, Arnaud, Boué, Jérôme, Blanpied, Catherine, Cenac, Nicolas, Laffont, Sophie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 2
container_start_page 215
container_title Journal of gastroenterology
container_volume 53
creator Basso, Lilian
Garnier, Laure
Bessac, Arnaud
Boué, Jérôme
Blanpied, Catherine
Cenac, Nicolas
Laffont, Sophie
description Background Endogenous opioids, including enkephalins, are fundamental regulators of pain. In inflammatory conditions, the local release of opioids by leukocytes at the inflammatory site inhibits nociceptor firing, thereby inducing analgesia. Accordingly, in chronic intestinal T.sub.h1/T.sub.h17-associated inflammation, enkephalins released by colitogenic CD4.sup.+ T lymphocytes relieve inflammation-induced visceral pain. The present study aims to investigate whether mucosal T-cell-derived enkephalins also exhibit a potent anti-inflammatory activity as described for exogenous opioid drugs in T.sub.h1/T.sub.h17-associated colitis. Methods The anti-inflammatory effects of endogenous opioids were investigated in both T.sub.h1/T.sub.h17-associated (transfer of CD4.sup.+CD45RB.sup.high T lymphocytes) and T.sub.h2-associated (oxazolone) colitis models in mice. Inflammation-induced colonic damage and CD4.sup.+ T cell subsets were compared in mice treated or not treated with naloxone methiodide, a peripheral antagonist of opioid receptors. The anti-inflammatory activity of T-cell-derived enkephalins was further estimated by comparison of colitis severity in immunodeficient mice into which naïve CD4.sup.+CD45RB.sup.high T lymphocytes originating from wild-type or enkephalin-knockout mice had been transferred. Results Peripheral opioid receptor blockade increases the severity of T.sub.h1/T.sub.h17-induced colitis and attenuates T.sub.h2 oxazolone colitis. The opposite effects of naloxone methiodide treatment in these two models of intestinal inflammation are dependent on the potency of endogenous opioids to promote a T.sub.h2-type immune response. Accordingly, the transfer of enkephalin-deficient CD4.sup.+CD45RB.sup.high T lymphocytes into immunodeficient mice exacerbates inflammation-induced colonic injury. Conclusions Endogenous opioids, including T-cell-derived enkephalins, promote a T.sub.h2-type immune response, which, depending on the context, may either attenuate (T.sub.h1/T.sub.h17-associated) or aggravate (T.sub.h2-associated) intestinal inflammation.
doi_str_mv 10.1007/s00535-017-1341-2
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A714583405</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714583405</galeid><sourcerecordid>A714583405</sourcerecordid><originalsourceid>FETCH-LOGICAL-g675-cfa63d8d840b6e8d0e00385f7146f43539c466a62263ee98390de595455a4fed3</originalsourceid><addsrcrecordid>eNptUE1LAzEUzEHBWv0B3gKes33ZfGz2WIpfUPCyZ0uavHSj22xptkL_vQEVPMh7MMPwZhgeIXccKg7QLDKAEooBbxgXkrP6gsyglZJx3sgrcp3zOwAXoMyMvHVsOO8P_ejOEzKPx_iJnmL6wENvh5gyPaI_OaRdlU_bqueLX9JQNw5xipna5KnNeXTRTsV8sDHRsvvo8IZcBjtkvP3BOekeH7rVM1u_Pr2slmu2041iLlgtvPFGwlaj8YAAwqjQcKmDFEq0TmptdV1rgdga0YJH1SqplJUBvZiT--_YnR1wE1MYp6N1-5jdZllClBGyvGROqn-uyngsXceEIRb9j-ELIQViLQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>T-lymphocyte-derived enkephalins reduce T.sub.h1/T.sub.h17 colitis and associated pain in mice</title><source>Springer Nature - Complete Springer Journals</source><creator>Basso, Lilian ; Garnier, Laure ; Bessac, Arnaud ; Boué, Jérôme ; Blanpied, Catherine ; Cenac, Nicolas ; Laffont, Sophie</creator><creatorcontrib>Basso, Lilian ; Garnier, Laure ; Bessac, Arnaud ; Boué, Jérôme ; Blanpied, Catherine ; Cenac, Nicolas ; Laffont, Sophie</creatorcontrib><description>Background Endogenous opioids, including enkephalins, are fundamental regulators of pain. In inflammatory conditions, the local release of opioids by leukocytes at the inflammatory site inhibits nociceptor firing, thereby inducing analgesia. Accordingly, in chronic intestinal T.sub.h1/T.sub.h17-associated inflammation, enkephalins released by colitogenic CD4.sup.+ T lymphocytes relieve inflammation-induced visceral pain. The present study aims to investigate whether mucosal T-cell-derived enkephalins also exhibit a potent anti-inflammatory activity as described for exogenous opioid drugs in T.sub.h1/T.sub.h17-associated colitis. Methods The anti-inflammatory effects of endogenous opioids were investigated in both T.sub.h1/T.sub.h17-associated (transfer of CD4.sup.+CD45RB.sup.high T lymphocytes) and T.sub.h2-associated (oxazolone) colitis models in mice. Inflammation-induced colonic damage and CD4.sup.+ T cell subsets were compared in mice treated or not treated with naloxone methiodide, a peripheral antagonist of opioid receptors. The anti-inflammatory activity of T-cell-derived enkephalins was further estimated by comparison of colitis severity in immunodeficient mice into which naïve CD4.sup.+CD45RB.sup.high T lymphocytes originating from wild-type or enkephalin-knockout mice had been transferred. Results Peripheral opioid receptor blockade increases the severity of T.sub.h1/T.sub.h17-induced colitis and attenuates T.sub.h2 oxazolone colitis. The opposite effects of naloxone methiodide treatment in these two models of intestinal inflammation are dependent on the potency of endogenous opioids to promote a T.sub.h2-type immune response. Accordingly, the transfer of enkephalin-deficient CD4.sup.+CD45RB.sup.high T lymphocytes into immunodeficient mice exacerbates inflammation-induced colonic injury. Conclusions Endogenous opioids, including T-cell-derived enkephalins, promote a T.sub.h2-type immune response, which, depending on the context, may either attenuate (T.sub.h1/T.sub.h17-associated) or aggravate (T.sub.h2-associated) intestinal inflammation.</description><identifier>ISSN: 0944-1174</identifier><identifier>DOI: 10.1007/s00535-017-1341-2</identifier><language>eng</language><publisher>Springer</publisher><subject>Analysis ; Care and treatment ; Colitis ; Enkephalins ; Inflammation ; Opioids ; Pain ; T cells</subject><ispartof>Journal of gastroenterology, 2018-02, Vol.53 (2), p.215</ispartof><rights>COPYRIGHT 2018 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Basso, Lilian</creatorcontrib><creatorcontrib>Garnier, Laure</creatorcontrib><creatorcontrib>Bessac, Arnaud</creatorcontrib><creatorcontrib>Boué, Jérôme</creatorcontrib><creatorcontrib>Blanpied, Catherine</creatorcontrib><creatorcontrib>Cenac, Nicolas</creatorcontrib><creatorcontrib>Laffont, Sophie</creatorcontrib><title>T-lymphocyte-derived enkephalins reduce T.sub.h1/T.sub.h17 colitis and associated pain in mice</title><title>Journal of gastroenterology</title><description>Background Endogenous opioids, including enkephalins, are fundamental regulators of pain. In inflammatory conditions, the local release of opioids by leukocytes at the inflammatory site inhibits nociceptor firing, thereby inducing analgesia. Accordingly, in chronic intestinal T.sub.h1/T.sub.h17-associated inflammation, enkephalins released by colitogenic CD4.sup.+ T lymphocytes relieve inflammation-induced visceral pain. The present study aims to investigate whether mucosal T-cell-derived enkephalins also exhibit a potent anti-inflammatory activity as described for exogenous opioid drugs in T.sub.h1/T.sub.h17-associated colitis. Methods The anti-inflammatory effects of endogenous opioids were investigated in both T.sub.h1/T.sub.h17-associated (transfer of CD4.sup.+CD45RB.sup.high T lymphocytes) and T.sub.h2-associated (oxazolone) colitis models in mice. Inflammation-induced colonic damage and CD4.sup.+ T cell subsets were compared in mice treated or not treated with naloxone methiodide, a peripheral antagonist of opioid receptors. The anti-inflammatory activity of T-cell-derived enkephalins was further estimated by comparison of colitis severity in immunodeficient mice into which naïve CD4.sup.+CD45RB.sup.high T lymphocytes originating from wild-type or enkephalin-knockout mice had been transferred. Results Peripheral opioid receptor blockade increases the severity of T.sub.h1/T.sub.h17-induced colitis and attenuates T.sub.h2 oxazolone colitis. The opposite effects of naloxone methiodide treatment in these two models of intestinal inflammation are dependent on the potency of endogenous opioids to promote a T.sub.h2-type immune response. Accordingly, the transfer of enkephalin-deficient CD4.sup.+CD45RB.sup.high T lymphocytes into immunodeficient mice exacerbates inflammation-induced colonic injury. Conclusions Endogenous opioids, including T-cell-derived enkephalins, promote a T.sub.h2-type immune response, which, depending on the context, may either attenuate (T.sub.h1/T.sub.h17-associated) or aggravate (T.sub.h2-associated) intestinal inflammation.</description><subject>Analysis</subject><subject>Care and treatment</subject><subject>Colitis</subject><subject>Enkephalins</subject><subject>Inflammation</subject><subject>Opioids</subject><subject>Pain</subject><subject>T cells</subject><issn>0944-1174</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptUE1LAzEUzEHBWv0B3gKes33ZfGz2WIpfUPCyZ0uavHSj22xptkL_vQEVPMh7MMPwZhgeIXccKg7QLDKAEooBbxgXkrP6gsyglZJx3sgrcp3zOwAXoMyMvHVsOO8P_ejOEzKPx_iJnmL6wENvh5gyPaI_OaRdlU_bqueLX9JQNw5xipna5KnNeXTRTsV8sDHRsvvo8IZcBjtkvP3BOekeH7rVM1u_Pr2slmu2041iLlgtvPFGwlaj8YAAwqjQcKmDFEq0TmptdV1rgdga0YJH1SqplJUBvZiT--_YnR1wE1MYp6N1-5jdZllClBGyvGROqn-uyngsXceEIRb9j-ELIQViLQ</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Basso, Lilian</creator><creator>Garnier, Laure</creator><creator>Bessac, Arnaud</creator><creator>Boué, Jérôme</creator><creator>Blanpied, Catherine</creator><creator>Cenac, Nicolas</creator><creator>Laffont, Sophie</creator><general>Springer</general><scope/></search><sort><creationdate>20180201</creationdate><title>T-lymphocyte-derived enkephalins reduce T.sub.h1/T.sub.h17 colitis and associated pain in mice</title><author>Basso, Lilian ; Garnier, Laure ; Bessac, Arnaud ; Boué, Jérôme ; Blanpied, Catherine ; Cenac, Nicolas ; Laffont, Sophie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g675-cfa63d8d840b6e8d0e00385f7146f43539c466a62263ee98390de595455a4fed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Analysis</topic><topic>Care and treatment</topic><topic>Colitis</topic><topic>Enkephalins</topic><topic>Inflammation</topic><topic>Opioids</topic><topic>Pain</topic><topic>T cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Basso, Lilian</creatorcontrib><creatorcontrib>Garnier, Laure</creatorcontrib><creatorcontrib>Bessac, Arnaud</creatorcontrib><creatorcontrib>Boué, Jérôme</creatorcontrib><creatorcontrib>Blanpied, Catherine</creatorcontrib><creatorcontrib>Cenac, Nicolas</creatorcontrib><creatorcontrib>Laffont, Sophie</creatorcontrib><jtitle>Journal of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Basso, Lilian</au><au>Garnier, Laure</au><au>Bessac, Arnaud</au><au>Boué, Jérôme</au><au>Blanpied, Catherine</au><au>Cenac, Nicolas</au><au>Laffont, Sophie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>T-lymphocyte-derived enkephalins reduce T.sub.h1/T.sub.h17 colitis and associated pain in mice</atitle><jtitle>Journal of gastroenterology</jtitle><date>2018-02-01</date><risdate>2018</risdate><volume>53</volume><issue>2</issue><spage>215</spage><pages>215-</pages><issn>0944-1174</issn><abstract>Background Endogenous opioids, including enkephalins, are fundamental regulators of pain. In inflammatory conditions, the local release of opioids by leukocytes at the inflammatory site inhibits nociceptor firing, thereby inducing analgesia. Accordingly, in chronic intestinal T.sub.h1/T.sub.h17-associated inflammation, enkephalins released by colitogenic CD4.sup.+ T lymphocytes relieve inflammation-induced visceral pain. The present study aims to investigate whether mucosal T-cell-derived enkephalins also exhibit a potent anti-inflammatory activity as described for exogenous opioid drugs in T.sub.h1/T.sub.h17-associated colitis. Methods The anti-inflammatory effects of endogenous opioids were investigated in both T.sub.h1/T.sub.h17-associated (transfer of CD4.sup.+CD45RB.sup.high T lymphocytes) and T.sub.h2-associated (oxazolone) colitis models in mice. Inflammation-induced colonic damage and CD4.sup.+ T cell subsets were compared in mice treated or not treated with naloxone methiodide, a peripheral antagonist of opioid receptors. The anti-inflammatory activity of T-cell-derived enkephalins was further estimated by comparison of colitis severity in immunodeficient mice into which naïve CD4.sup.+CD45RB.sup.high T lymphocytes originating from wild-type or enkephalin-knockout mice had been transferred. Results Peripheral opioid receptor blockade increases the severity of T.sub.h1/T.sub.h17-induced colitis and attenuates T.sub.h2 oxazolone colitis. The opposite effects of naloxone methiodide treatment in these two models of intestinal inflammation are dependent on the potency of endogenous opioids to promote a T.sub.h2-type immune response. Accordingly, the transfer of enkephalin-deficient CD4.sup.+CD45RB.sup.high T lymphocytes into immunodeficient mice exacerbates inflammation-induced colonic injury. Conclusions Endogenous opioids, including T-cell-derived enkephalins, promote a T.sub.h2-type immune response, which, depending on the context, may either attenuate (T.sub.h1/T.sub.h17-associated) or aggravate (T.sub.h2-associated) intestinal inflammation.</abstract><pub>Springer</pub><doi>10.1007/s00535-017-1341-2</doi></addata></record>
fulltext fulltext
identifier ISSN: 0944-1174
ispartof Journal of gastroenterology, 2018-02, Vol.53 (2), p.215
issn 0944-1174
language eng
recordid cdi_gale_infotracmisc_A714583405
source Springer Nature - Complete Springer Journals
subjects Analysis
Care and treatment
Colitis
Enkephalins
Inflammation
Opioids
Pain
T cells
title T-lymphocyte-derived enkephalins reduce T.sub.h1/T.sub.h17 colitis and associated pain in mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T14%3A54%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=T-lymphocyte-derived%20enkephalins%20reduce%20T.sub.h1/T.sub.h17%20colitis%20and%20associated%20pain%20in%20mice&rft.jtitle=Journal%20of%20gastroenterology&rft.au=Basso,%20Lilian&rft.date=2018-02-01&rft.volume=53&rft.issue=2&rft.spage=215&rft.pages=215-&rft.issn=0944-1174&rft_id=info:doi/10.1007/s00535-017-1341-2&rft_dat=%3Cgale%3EA714583405%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A714583405&rfr_iscdi=true